IMRX Director Buys 7,500 Shares at $6.67 — Insider Filing

Insider purchase by Director Peter Feinberg.

Rhea-AI Filing Summary

Insider purchase by Director Peter Feinberg. The filing shows a purchase of 7,500 shares of Class A common stock on 10/03/2025 at a reported price of $6.67 per share. After the transaction, Mr. Feinberg directly owns 156,766 shares and indirectly beneficially owns larger stakes through entities: 392,242, 476,615, and 115,441 shares via three general‑partner relationships, bringing total reported beneficial holdings across direct and indirect positions to a material position in the company.

Positive

• Insider purchase recorded: Director bought 7,500 shares at $6.67, indicating personal capital investment
• Substantial beneficial ownership: Reported indirect holdings of 392,242, 476,615, and 115,441 shares increase long‑term alignment

Negative

• None.

Insights

Corporate Governance Analyst

Director purchase signals management alignment with shareholders.

Director Peter Feinberg reported a direct purchase of $6.67 per share for 7,500 Class A shares on 10/03/2025

The holding structure shows both direct and significant indirect ownership via three entities (reported amounts: 392,242, 476,615, 115,441 shares), which increases his overall economic exposure. Investors often view insider purchases as a governance signal; this is an observable, disclosed transaction with clear share counts and price.

Monitor subsequent Form 4 filings and any scheduled lockups or equity plans for changes to these positions over the next 30–90 days.

Insider Trade Summary

Net Buyer: 7,500 shares

Net Buy 4 txns

Insider Feinberg Peter

Role Director

Bought 7,500 shs ($50K)

Type	Security	Shares	Price	Value
Purchase	Class A Common Stock	7,500	$6.67	$50K
holding	Class A Common Stock	--	--	--
holding	Class A Common Stock	--	--	--
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Class A Common Stock — 156,766 shares (Direct); Class A Common Stock — 392,242 shares (Indirect, General Partner of PF Associates L.P.); Class A Common Stock — 476,615 shares (Indirect, General Partner of PEF LLC.); Class A Common Stock — 115,441 shares (Indirect, General Partner of S4K Investments LLC.)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did Peter Feinberg report on Form 4 for IMRX?

He reported a direct purchase of 7,500 Class A shares on 10/03/2025 at $6.67 per share.

How many shares does Peter Feinberg own after the reported transaction?

He directly owns 156,766 Class A shares following the transaction, plus indirect holdings of 392,242, 476,615, and 115,441 shares through affiliated entities.

What is Peter Feinberg's relationship to Immuneering Corp (IMRX)?

He is reported as a Director of Immuneering Corp.

When was the Form 4 signed and filed?

The signature by attorney‑in‑fact is dated 10/07/2025, and the transaction date is 10/03/2025.

Did the filing disclose any derivative transactions?

No. Table II (derivative securities) shows no reported transactions or holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/07/2025 - 08:56 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Feinberg Peter

(Last) (First) (Middle)

245 MAIN STREET

SECOND FLOOR

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immuneering Corp [ IMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	10/03/2025		P		7,500	A	$6.67	156,766	D
Class A Common Stock								392,242	I	General Partner of PF Associates L.P.
Class A Common Stock								476,615	I	General Partner of PEF LLC.
Class A Common Stock								115,441	I	General Partner of S4K Investments LLC.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Michael D. Bookman, Attorney-in-Fact for Peter Feinberg	10/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.